期刊文献+

曲美他嗪与低分子肝素治疗不稳定型心绞痛临床观察 被引量:8

Clinical Observation of Low Molecular Weight Heparin Combined with Trimetazidine on the Treatment of Unstable Angina Pectoris
下载PDF
导出
摘要 目的:观察低分子肝素与曲美他嗪治疗不稳定型心绞痛(UAP)的疗效。方法:172例UAP患者随机分为2组,其中对照组88例;两组均常规给予硝酸酯类、β-受体阻滞剂及阿司匹林等;治疗给予低分子肝素钠4000 IU,2次/d,皮下注射,连用5~7d,加用曲美他嗪20mg,每日3次及心电图改变情况。结果:治疗组临床总有效率为90.91%,对照组总有效率为69.05%,治疗组明显优于对照组(P〈0.01)。治疗后治疗组ST段下降导联数(NST)ST段下降的数值总和(ΣST)及心肌缺血总负荷均较治疗前显著改善(P〈0.01)。治疗组有5例皮下瘀斑,2例进展为AMI;而对照组有8例进展为AMI。结论:低分子肝素联用曲美他嗪,治疗UAP安全有效。 Objective: To observe the effect of low molecular weight heparin combined with trimnetazidine on the treatment of unstable angina pectoris (UAP). Method: Eightysix patients with UAP were divided into two groups. There were 84 patients in the treatment group and 88 patients in the control group. Allof them were given the nitroglycerin, beta - blockers and aspirinetc. Treatment group were used the low molecular weight heparin 4000IU, twice a day hypodermic, after five to seven days, added the trimetazidine 20 mg, three times a day ,it was used 15 days. The control group was used heparin sodium 5000IU,twice a day hypodermic,it was used five to seven days. Result: The total effective rate of the treatment group was 90.91% and the control group was 69.05%, the treatment group was much better than the control group ( P 〈 0.01 ). The treatment group contained 5 cases of subcutaneous purpura, and only 2 patients witn AMI, but the control group has 8 patients with AMI . All the patients were treated with coronary interventional therapy. Conclusion: The low molecular weight heparin combined with trimteazidine is more safety and effectively on UAP.
作者 刘文铠
出处 《河北医学》 CAS 2008年第2期132-134,共3页 Hebei Medicine
关键词 低分子肝素 曲美他嗪 心绞痛 不稳定型 Low molecular weight heparin. Trimetazidine Angina pectoric Unstable
  • 相关文献

参考文献6

二级参考文献18

  • 1石海莉,孙漾丽.曲美他嗪治疗不稳定型心绞痛的临床疗效[J].临床心血管病杂志,2005,21(9):560-561. 被引量:30
  • 2张学民,冯丰.曲美他嗪治疗稳定型心绞痛42例疗效观察[J].疑难病杂志,2006,5(4):280-280. 被引量:14
  • 3Lopaschuk GD.Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism[J].Am J Cardiol,1998,82(5A):14k-17k.
  • 4Kantor P,Lucien A,Kozak R,et al .The antiangial drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain-3-ketoacy1 coenzyme A thiolase .Circ Res,2000,86:580-588.
  • 5Eugene B, Elliott M, John W,et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive Summary and Recommendations. Circulation, 2000,102:1193-1209.
  • 6许俊堂 胡大一 丛玉隆.心血管血栓的溶栓及抗凝疗法[M].北京:人民卫生出版社,2000.22-26.
  • 7Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J].Circ Res,2000,86(6):568-580.
  • 8Szwed H,Pachocki R,Domzal-Bochenska M,et al.Efficacy and tolerance of trimetazidine in combination with a conventional antianginal drug in patients with stable effort angina[J].Diagn Treat Cardiol,1997,4:237-247.
  • 9C. Monpère,M. Brochier,J. Demange,G. Ducloux,J.F. Warin. Combination of trimetazidine with nifedipine in effort angina[J] 1990,Cardiovascular Drugs and Therapy(4):824~825
  • 10Sergio Dalla-Volta,Giuseppe Maraglino,Patricia Della-Valentina,Pietro Viena,Alessandro Desideri. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study[J] 1990,Cardiovascular Drugs and Therapy(4):853~859

共引文献2899

同被引文献30

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部